Journal List > Endocrinol Metab > v.32(2) > 1086348

Beano, Zmaili, Gheith, Naser, Momani, Yousef, and Zayed: Predetermined Anti-Diabetic Drug Regimen Adjustments during Ramadan Fasting: An Observational Study of Safety



Many Muslim type 2 diabetes mellitus (T2DM) patients choose to fast the month of Ramadan despite the possible adverse health effects brought about by the change in dietary habits, among other things. Clinical data regarding the safety of multi-drug regimens during fasting are particularly scarce. The aim of the study was to evaluate the safety of a drug protocol devised by the authors to accommodate Ramadan's dietary changes, involving dose adjustments of four anti-diabetic drug regimens in T2DM patients fasting Ramadan.


In this prospective, observational, open-label study, 301 T2DM patients who wished to fast Ramadan were followed during Ramadan and the preceding month. The incidence of hypoglycemia, diabetic ketoacidosis (DKA) and non-ketotic hyperosmolar state (NKHS) was monitored. Patients were classified into four groups: A group (those taking metformin, sulfonylurea and insulin [n=33]); B group (metformin and sulfonylurea [n=89]); C group (metformin and insulin [n=96]); and D group (premixed 70/30, glargine or regular insulin [n=82]). During Ramadan, drug doses were adjusted as percentages of their pre-Ramadan values: 75% for sulfonylureas, 75% for glargine, 75% for premixed insulin 70/30 in two doses, and 75% for regular insulin. Metformin was adjusted to a twice-daily regimen.


No cases of DKA or NKHS were reported. Hypoglycemia occurred at a lower rate than pre-Ramadan values in groups C, and D; and a similar rate in groups A, and B.


The data suggested that using the above protocol to adjust the doses of anti-diabetic drugs is safe in T2DM patients in regards to hypoglycemia, DKA, and NKHS.


With dietary modification being a cornerstone of the management of diabetes, physicians must be ready to deal with peculiar dietary choices when managing patients with diabetes. An example of such patients is Muslim patients wishing to fast Ramadan, the 9th lunar month. The religious Ramadan fast entails abstaining from food and drink from dawn till sunset. Traditionally, Muslims break their fast with a meal at sunset (also called Iftar), followed by a second meal before dawn (Suhur), with variable snacks during the course of the night [1]. Although chronic illness exempts Muslims from this fast (Quran 2:183–185), many patients with diabetes choose to fast [2] in face of the possible adverse effects to their health, including hypoglycemia, diabetic ketoacidosis (DKA), and non-ketotic hyperosmolar state (NKHS) [2], in addition to dehydration, thrombosis, stroke, and retinal artery occlusion [3].
Nevertheless, the choice to fast remains a personal one, necessitating the study of safe diabetes management during Ramadan. The consensus favors the individualization of treatment [4567 8], with certain clinical trials providing more details for specific anti-diabetic drug therapies [910111213]. However, clinical data with regard to the safety of multi-drug regimens during fasting are particularly scarce, with the majority focusing on dual drug therapies and comparing only two-drug-regimens. To the best of the authors' knowledge, the only study to compare more than two drugs during Ramadan included three drugs; glimepiride, repaglinide, and insulin glargine and included 49 type 2 diabetes mellitus (T2DM) patients and 16 controls [14]. The aim of this study was to assess the safety of a protocol involving dose adjustments to four different anti-diabetic drug regimens in T2DM patients who chose to fast during Ramadan. These regimens included five drugs: sulfonylureas, metformin, insulin glargine, regular insulin and premixed insulin 70/30 (30% regular insulin and 70% isophane insulin), which are among the most commonly used and widely accessible management options for T2DM.


Study design and patient selection

This prospective, observational, open-label study was conducted at the Endocrinology and Diabetes Clinics at Jordan University Hospital (JUH), Amman, Jordan, and spanned the month of Ramadan and the preceding month (from May 28, 2014 to July 27, 2014). The study was approved by the Institutional Review Board of the hospital and was carried out in accordance to the Ethical Principles for Medical Research Involving Human Subjects outlined in the Declaration of Helsinki. Written forms of consent were acquired from all of the participating patients.
A total of 468 patients were enrolled at the start of the study. Volunteers were sought among the Muslim T2DM patients attending the Endocrinology and Diabetes Clinics for their regular visits, with no incentives rewarded. As a criterion for enrollment, patients had to be consenting adults with a baseline glycated hemoglobin (HbA1c) value greater than 6.5% (48 mmol/mol) and less than 10% (86 mmol/mol). To avoid serum glucose fluctuations, only those who had been on a constant anti-diabetic drug regimen for at least 3 months before the study period were included.
Patients with any degree of cognitive dysfunction that might have impaired their capacity to provide consent were excluded, as were those older than 75 years, in whom the complications of poor glycemic control were deemed too dangerous. Additionally, female patients of reproductive age were excluded because females are exempted from fasting during their menstrual periods. Other causes of ineligibility included pregnant females up to 6 weeks postpartum; lactating females; patients with hypoglycemic unawareness, liver cirrhosis, renal impairment (defined as serum creatinine ≥1.5 mg/dL and/or an estimated creatinine clearance <40 mL/min/1.72 m2), or unstable seizure disorder; and patients with a history of depression, bipolar disorder, psychosis, or recurrent severe hypoglycemic attacks. Patients with recent histories of niacin or steroid therapy (within the month prior to the trial) or DKA or NKHS (within 3 months prior to the trial) were also excluded. Finally, patients living alone were excluded because those patients are less likely to receive rapid assistance if complications were to occur.
At least 2 weeks before the study period, the eligible patients were asked to come in for a screening visit, during which appropriate medical counseling was provided orally by the same physician regarding the risks of fasting and the need to modify treatment regimens during Ramadan. Guidance was also provided as to the importance of complying with the treatment, consuming meals regularly, identifying and treating hypoglycemia, and breaking the fast immediately whenever the patients' health required it, including hypoglycemia. No modifications to the patients' baseline exercise or dietary habits were made so that they could continue the study period as normally as they would to better mimic real life. A detailed patient history was then taken, and a thorough physical exam was performed, after which a blood sample was drawn for the following tests: serum creatinine, electrolytes, liver function, fasting lipid profile, complete blood count, glucose, and HbA1c. For these tests, blood samples were drawn from the fasting patients by trained medical residents at the clinic and were immediately sent to the local laboratory at JUH.
The enrolled patients were then divided into the following four groups according to their medication regimen: group A (metformin, sulfonylurea [glimepiride] and insulin); group B (metformin and sulfonylurea [glimepiride]); group C (metformin and insulin); and group D (insulin alone). Notably, the patients were not started on these drug regimens for the purpose of the study; rather, the groups were devised after enrollment of patients, utilizing only the medications they were already using to ensure the patients' convenience, no one was asked to change the type of drug(s) that he or she was taking; instead, only the dosages were changed. The changes made are summarized in Table 1. Other than these dose modifications, the patients' baseline treatment regimens were kept constant.
The above modifications were decided by the authors of this study and were guided by an unpublished pilot study conducted by the authors during Ramadan 2013, in which two groups of Muslim patients with T2DM and aged 40 to 70 years were prospectively studied. The same inclusion and exclusion criteria as used in the present study were used then, as well as the same anti-diabetic drugs, albeit using different dosing regimens. The first group (n=79) was divided to four subgroups according to their medication regimen, subgroup A (n=19) metformin, glimepiride, and insulin; subgroup B (n=21) metformin and glimepiride; subgroup C (n=20) metformin and insulin; and subgroup D (n=19) insulin alone. The doses of their anti-diabetic drugs were decreased by 50% during Ramadan. The other group (n=75) was also divided to four subgroups: subgroup A (n=18); subgroup B (n=19); subgroup C (n=19); and subgroup D (n=19). The medication regimen of these subgroups was similar to that of the first group. However the doses were decreased by 25% rather than 50%. Although there was no significant difference in the incidence of hypoglycemia, DKA, or NKHS between the two groups, 11 patients from group 1 (five from subgroup C and six from subgroup D) visited the emergency department due to profound hyperglycemia (defined as plasma glucose >400 mg/dL), compared with only one patient from group 2 (subgroup D) (P=0.005).

Study endpoints

The study's primary endpoint was the incidence of hypoglycemia, DKA, or NKHS among the patients during Ramadan compared within the preceding month, serving as measures of the proposed protocol's safety.
Hypoglycemia was defined as a serum glucose level of less than 70 mg/dL [15] along with symptoms or with blood glucose of 60 mg/dL or less regardless of symptoms [16]. Severe hypoglycemia was defined as a hypoglycemic episode requiring assistance from another person [15].
The patients were provided with diary cards to record any symptoms and their timing and were instructed to perform finger-stick glucose measurements (FSGMs) before each meal and at bedtime during the month preceding Ramadan. During Ramadan, the FSGMs were to be obtained before Suhur, at noon, before Iftar and 2 hours post-Iftar. Furthermore, the patients were asked to record the number, details and symptoms of any episodes of hypoglycemia, DKA, and NKHS, in addition to the details of and reasons for any hospital or emergency room visits. Moreover, the patients were scheduled for weekly follow-up visits during Ramadan and the preceding month, at which they were asked about the above information to confirm the data in the diary cards.
At the final follow-up visit at the end of Ramadan, the following information was obtained by means of a questionnaire and an oral interview with one of the authors of this study: confirmation of fasting during Ramadan, the number and details of hypoglycemic episodes, and the development of DKA or NKHS during Ramadan and the preceding month. The patients were also assessed for compliance with their treatment regimens during the study period by reviewing their diary cards.

Statistical analysis

The primary outcomes were the frequency of hypoglycemia, DKA and NKHS before Ramadan and at the end of the 29-day fasting period. Changes in the frequency of hypoglycemia were tested using a binomial test because the counts of subjects with positive responses were small. A P value of less than 0.05 was the cutoff for significance. Backward stepwise regression revealed that the baseline values of the patients' age, HbA1c, body mass index, duration of diabetes, and the patients' sex did not have any relationship with the frequency of hypoglycemia before Ramadan.


A total of 468 patients were enrolled in the study, of which 167 were excluded from data analysis after enrollment (Fig. 1). Among the excluded patients, 142 were excluded for being lost to follow-up or returning incomplete diary cards, and were distributed equally among the treatment groups (group A, 30.6%; group B, 32.6%; group C, 31.0%; group D, 32.8%; P=0.981), with an overall rate of 31.9%. In addition, there was no statistically significant difference in the baseline characteristics between he included and excluded groups Table 2. The other 25 patients excluded for non-adherence to fasting or non-compliance to medication were not expected to significantly introduce bias. None of the patients died during the study. Of the 301 patients included 139 (46.2%) were male, with a mean age of 58.5±11.2 years. All patients were Arabs.
The detailed results for the four categories of patients were as follows (Table 3). Group A received metformin, sulfonylurea, and insulin and included 34 patients. The number of hypoglycemic episodes during the month before Ramadan (pre-Ramadan) was two, compared to none during Ramadan (P=0.498) (Table 4).
Group B (n=89) received metformin and sulfonylurea and was divided into two subgroups according to glimepiride dosage: 62 patients received 4 mg of glimepiride; the rest received 2 mg. Three episodes of hypoglycemia were reported pre-Ra-madan and none during Ramadan (P=0.252).
Group C (n=96) received metformin and insulin. Fifty-eight received insulin glargine, while 38 received premixed insulin 70/30. Nine episodes of hypoglycemia occurred pre-Ramadan and only one episode during Ramadan (P=0.008).
Group D (n=82) received insulin only; 51 patients received insulin glargine plus regular insulin, the rest received premixed insulin 70/30 only. There were seven reported episodes of hypoglycemia pre-Ramadan and none during Ramadan (P=0.016).
No episodes of severe hypoglycemia were observed (Fig. 2); all fell under the category of symptomatic hypoglycemia and were self-treated by the patients without seeking professional medical assistance and with no further complications. The characteristics of the patients who suffered a hypoglycemic episode in each group before and during Ramadan are shown in Table 4. Furthermore, no cases of DKA or NKHS were reported during the study period in any of the treatment groups. A statistical analysis of the demographic data revealed no sources of confounding bias.


This prospective, observational, open-label study demonstrated that none of the four groups showed any significant increase in the incidence of the three examined complications: hypoglycemia, DKA, and NKHS. Furthermore, groups C and D showed significant decreases in the incidence of hypoglycemia during Ramadan compared within the preceding month. Therefore, the four proposed drug regimens appear to be safe for use during Ramadan by T2DM patients who choose to fast.
The literature concerning the safety of multi-drug regimens during Ramadan is sparse, with most studies and recommendations focusing on and comparing the safety of monotherapies, rather than multi-drug regimens, during Ramadan [45689111417181920]. Accordingly, many studies have been performed to assess the safety of different anti-diabetic medications during fasting among diabetic patients who insist on fasting during Ramadan [121721]. Many of those studies have reported the incidence of acute glycemic complications (mainly hypoglycemia). Several of those studies were undertaken to compare the safety of one oral anti-diabetic drug with that of another [121721]. Other studies have addressed safety during fasting by switching the dose of an anti-diabetic drug usually taken in the morning to the evening [20]. Other studies have compared hypoglycemic events in patients receiving Humalog Mix 50 (Lilly, Indianapolis, IN, USA) with those in patients treated with human insulin Mix 30 [11].
Metformin is recommended because of the low risk of hypoglycemia associated with its use, although the dose schedule must be altered to accommodate changes in meal patterns during Ramadan [48]. Additionally, many patients with diabetes require additional anti-hyperglycemic medications to manage their disease [22]. Therefore, sulfonylureas are typically recommended in combination with metformin based on broad clinical experience and their low cost [23]. Nevertheless, Salti and Diabetes and Ramadan Study Group [10] reported a hypoglycemia incidence rate of 24% in patients on insulin and sulfonylurea combination therapy during Ramadan. For sulfonylurea and metformin multi-therapy, that figure ranged between 7% and 62% [1213212425262728]; however, the two largest studies reported figures of 13% and 9%, respectively [1328], and these number might reflect the true values more accurately. For insulin mono-therapy, the reported rates of the incidence of hypoglycemia range from 1.6% [11] to 45% [19]. In one study by Cesur et al. [14], 49 T2DM patients who were fasting were treated with glimepiride, repaglinide, or insulin glargine and were compared with 16 non-fasting controls, and no significant difference in the incidence of hypoglycemia between the two groups was found. To the best of our knowledge, no studies concerning the safety of combination therapy with insulin, sulfonylurea, and metformin have been conducted.
A notable discrepancy between the rates of hypoglycemia during Ramadan reported in the current study and those in the literature is thus apparent. It is the opinion of the authors that this difference stems from the proposed modifications to the four drug regimens, especially given that a number of the articles referenced above did not change the dosages of the anti-diabetic drugs for the sampled population, i.e., the patients were kept on their pre-Ramadan regimens in terms of the total doses used [101112212527]. Moreover, the strict exclusion criteria employed in the present study might have played a role in the discrepancy. It could also be argued; however, that a closer patient-physician interaction and the attendance of pre-Ramadan educational sessions by the patients might have confounded the results of this investigation. The positive effects that patient education might have on the rates of hypoglycemia during Ramadan have been reported in literature before [29].
We feel obliged to elaborate on several of this study's strengths and limitations. To the best of our knowledge, there has not been a previous study comparing four different concurrent anti-diabetic regimens including sulfonylurea, metformin, insulin glargine, regular insulin, and/or premixed insulin. Additionally, we sought a practical approach to drug regimen modification, in that only the doses were modified, rather than the drugs themselves, relieving patients of having to learn about new medications. Moreover, in contrast to more expensive anti-diabetic drugs such as rapid acting insulin analogues and incretin based therapies, the drugs included in this study might appeal to a greater audience all the over the world due to less cost and thus easier accessibility.
As for the limitations, first, the study was not designed in a randomized control trial setting, which is the most appropriate for studies comparing different drug regimens. However, due to the limited patient population from which the sample was derived, a control group of similar demographics to the treatment group could not be assembled. The authors thus decided to use the treatment group's pre-Ramadan status as a form of control. Second, we relied on interviews and diary cards for data collection. However, diary cards have been criticized in the past as a method of data collection in terms of the accuracy of the data reported [30]. Of particular concern is the Hawthorn effect, in which individuals modify their behavior in reaction to being observed [31]. However, this false reporting bias in our case was similarly applicable to both months being studied (Ramadan and the preceding month). The authors also missed the opportunity to download data off of the patients' glucometers, which might have provided more evidence based conclusions. We were unable to obtain that data because of the financial limitations of some of the subjects who did not own a glucometer at home. Those patients relied on their neighborhood pharmacies or health centers to check their glucose levels. Third, females of reproductive age were excluded due to their generally shorter fasting period during Ramadan, since they are exempted from fasting during menstrual periods. As a result, the females who were included were all post-menopausal, which skewed the mean age of the sample population and possibly led to a false elevation in the incidence of hypoglycemia because advanced age is itself a risk factor for hypoglycemia. Nevertheless, the average age of the entire sample studied was approximately 59 years, which would classify the sample as middle-aged on average. Fourth, optimal glycemic control could not be accurately evaluated with the use of serum HbA1c since those values reflect the glycemic status of the preceding 3 months. The more suitable test for short term evaluation—serum fructosamine level—was unfortunately unavailable in the country. Finally, the sample sizes of groups A and B were relatively small, and the statistical power was less than 80%. Hence, the small sample size may contribute to the low incidence of hypoglycemia and no report of DKA or NKHS. Of note, analysis of the baseline characteristics of included and excluded patients did not show attrition bias.
In summary, this is the first study that investigated the safety of dose adjustments for four anti-diabetic drug regimens including a total of five drugs in T2DM patients fasting Ramadan. The lack of an increase in the incidence of the hypoglycemia, NKHS, and DKA endorses the safety of the proposed regimens for those patients.
We recommend further research into this subject. Larger studies could be designed with larger sample populations from different geographical locations, comparing the safety of more anti-diabetic drugs. Additionally, the efficacy of the proposed protocol in achieving glycemic control could be further investigated. Finally, studying the group of patients who dropped out and comparing them with the group that remained might be of interest.


CONFLICTS OF INTEREST: No potential conflict of interest relevant to this article was reported.


1. Al-Arouj M, Bouguerra R, Buse J, Hafez S, Hassanein M, Ibrahim MA, et al. Recommendations for management of diabetes during Ramadan. Diabetes Care. 2005; 28:2305–2311. PMID: 16123509.
2. Salti I, Benard E, Detournay B, Bianchi-Biscay M, Le Brigand C, Voinet C, et al. A population-based study of diabetes and its characteristics during the fasting month of Ramadan in 13 countries: results of the epidemiology of diabetes and Ramadan 1422/2001 (EPIDIAR) study. Diabetes Care. 2004; 27:2306–2311. PMID: 15451892.
3. Hassan A, Meo SA, Usmani AM, Shaikh TJ. Diabetes during Ramadan: pre-approach model: presentation, risk stratification, education. Eur Rev Med Pharmacol Sci. 2014; 18:1798–1805. PMID: 24992624.
4. Al-Arouj M, Assaad-Khalil S, Buse J, Fahdil I, Fahmy M, Hafez S, et al. Recommendations for management of diabetes during Ramadan: update 2010. Diabetes Care. 2010; 33:1895–1902. PMID: 20668157.
5. Karamat MA, Syed A, Hanif W. Review of diabetes management and guidelines during Ramadan. J R Soc Med. 2010; 103:139–147. PMID: 20382905.
6. Akbani MF, Saleem M, Gadit WU, Ahmed M, Basit A, Malik RA. Fasting and feasting safely during Ramadan in the patient with diabetes. Prac Diabetes Int. 2005; 22:100–104.
7. Pathan MF, Sahay RK, Zargar AH, Raza SA, Khan AK, Ganie MA, et al. South Asian consensus guideline: use of insulin in diabetes during Ramadan. Indian J Endocrinol Metab. 2012; 16:499–502. PMID: 22837903.
8. Almaatouq MA. Pharmacological approaches to the management of type 2 diabetes in fasting adults during Ramadan. Diabetes Metab Syndr Obes. 2012; 5:109–119. PMID: 22654520.
9. Zargar AH, Siraj M, Jawa AA, Hasan M, Mahtab H. Maintenance of glycaemic control with the evening administration of a long acting sulphonylurea in male type 2 diabetic patients undertaking the Ramadan fast. Int J Clin Pract. 2010; 64:1090–1094. PMID: 20455956.
10. Salti I. Diabetes and Ramadan Study Group. Efficacy and safety of insulin glargine and glimepiride in subjects with type 2 diabetes before, during and after the period of fasting in Ramadan. Diabet Med. 2009; 26:1255–1261. PMID: 20002478.
11. Hui E, Bravis V, Salih S, Hassanein M, Devendra D. Comparison of Humalog Mix 50 with human insulin Mix 30 in type 2 diabetes patients during Ramadan. Int J Clin Pract. 2010; 64:1095–1099. PMID: 20337752.
12. Devendra D, Gohel B, Bravis V, Hui E, Salih S, Mehar S, et al. Vildagliptin therapy and hypoglycaemia in Muslim type 2 diabetes patients during Ramadan. Int J Clin Pract. 2009; 63:1446–1450. PMID: 19678856.
13. Al Sifri S, Basiounny A, Echtay A, Al Omari M, Harman-Boehm I, Kaddaha G, et al. The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomised trial. Int J Clin Pract. 2011; 65:1132–1140. PMID: 21951832.
14. Cesur M, Corapcioglu D, Gursoy A, Gonen S, Ozduman M, Emral R, et al. A comparison of glycemic effects of glimepiride, repaglinide, and insulin glargine in type 2 diabetes mellitus during Ramadan fasting. Diabetes Res Clin Pract. 2007; 75:141–147. PMID: 16815586.
15. Workgroup on Hypoglycemia, American Diabetes Association. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care. 2005; 28:1245–1249. PMID: 15855602.
16. Boon NA, Davidson S, Britton R. Davidson's principles & practice of medicine. 20th ed. Edinburgh: Elsevier/Churchill Livingstone;2008.
17. Mafauzy M. Repaglinide versus glibenclamide treatment of type 2 diabetes during Ramadan fasting. Diabetes Res Clin Pract. 2002; 58:45–53. PMID: 12161056.
18. Mafauzy M, Mohammed WB, Anum MY, Zulkifli A, Ruhani AH. A study of the fasting diabetic patients during the month of Ramadan. Med J Malaysia. 1990; 45:14–17. PMID: 2152063.
19. Akram J, De Verga V. Insulin lispro (Lys(B28), Pro(B29) in the treatment of diabetes during the fasting month of Ramadan. Ramadan Study Group. Diabet Med. 1999; 16:861–866. PMID: 10547214.
20. Ahmed MH, Abdu TA. Diabetes and Ramadan: an update on use of glycemic therapies during fasting. Ann Saudi Med. 2011; 31:402–406. PMID: 21727749.
21. Hassanein M, Hanif W, Malik W, Kamal A, Geransar P, Lister N, et al. Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR study. Curr Med Res Opin. 2011; 27:1367–1374. PMID: 21568833.
22. Malik S, Lopez V, Chen R, Wu W, Wong ND. Undertreatment of cardiovascular risk factors among persons with diabetes in the United States. Diabetes Res Clin Pract. 2007; 77:126–133. PMID: 17118478.
23. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA. 2002; 287:360–372. PMID: 11790216.
24. Al-Arouj M, Hassoun AA, Medlej R, Pathan MF, Shaltout I, Chawla MS, et al. The effect of vildagliptin relative to sulphonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: the VIRTUE study. Int J Clin Pract. 2013; 67:957–963. PMID: 24001317.
25. Anwar A, Azmi KN, Hamidon BB, Khalid BA. An open label comparative study of glimepiride versus repaglinide in type 2 diabetes mellitus Muslim subjects during the month of Ramadan. Med J Malaysia. 2006; 61:28–35. PMID: 16708731.
26. Aravind SR, Al Tayeb K, Ismail SB, Shehadeh N, Kaddaha G, Liu R, et al. Hypoglycaemia in sulphonylurea-treated subjects with type 2 diabetes undergoing Ramadan fasting: a five-country observational study. Curr Med Res Opin. 2011; 27:1237–1242. PMID: 21506631.
27. Aravind SR, Ismail SB, Balamurugan R, Gupta JB, Wadhwa T, Loh SM, et al. Hypoglycemia in patients with type 2 diabetes from India and Malaysia treated with sitagliptin or a sulfonylurea during Ramadan: a randomized, pragmatic study. Curr Med Res Opin. 2012; 28:1289–1296. PMID: 22738801.
28. Hassanein M, Abdallah K, Schweizer A. A double-blind, randomized trial, including frequent patient-physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEADFAST study. Vasc Health Risk Manag. 2014; 10:319–326. PMID: 24920915.
29. Bravis V, Hui E, Salih S, Mehar S, Hassanein M, Devendra D. Ramadan Education and Awareness in Diabetes (READ) programme for Muslims with type 2 diabetes who fast during Ramadan. Diabet Med. 2010; 27:327–331. PMID: 20536496.
30. Stone AA, Shiffman S, Schwartz JE, Broderick JE, Hufford MR. Patient compliance with paper and electronic diaries. Control Clin Trials. 2003; 24:182–199. PMID: 12689739.
31. McCarney R, Warner J, Iliffe S, van Haselen R, Griffin M, Fisher P. The Hawthorne effect: a randomised, controlled trial. BMC Med Res Methodol. 2007; 7:30. PMID: 17608932.
Fig. 1

The number of enrolled subjects included and excluded from the data analysis.

Fig. 2

The prevalence of hypoglycemic episodes in each drug group before and during Ramadan. Group A (patients on metformin, glimepiride and insulin), B (patients on metformin and glimepiride), C (patients on metformin and insulin), and D (patients on insulin alone).

Table 1

Changes Made to the Anti-Diabetic Medication Regimens during Ramadan

Diabetic drug Total daily dose (pre-Ramadan) Modified Ramadan regimen
Iftara Suhurb
Metformin 1 g bidc 1 g 1 g
850 mg tidd 850 mg 850 mg
Sulfonylurea Glimepiride 2 or 4 mge 75% of the dose -
Glargine 10–65 unitsf 75% of the dose -
Regular insulin 15–75 unitsg 45% of the dose 30% of the dose
70% Isophane insulin and 30% regular insulin (premixed 70/30) 35–150 unitsg 45% of the dose 30% of the dose

bid, twice a day; tid, three times a day.

aIftar is the meal at sunset with which the fast is broken; bSuhur is a second meal, taken before dawn; cTaken with breakfast, and dinner; dTaken with breakfast, lunch, and dinner; eTaken with breakfast; fTaken at bedtime; gIn three divided doses taken 30 minutes before each meal.

Table 2

Comparison between the Included and Excluded Characteristics of the Subjects in Different Treatment Groupsa

Variable Group A Group B Group C Group D
Included Excluded P value Included Excluded P value Included Excluded P value Included Excluded P value
No. of patients in subgroup 34 15 - 89 43 - 96 43 - 82 40 -
Male sex 18 (52.9) 10 (66.7) 0.533 42 (47.2) 20 (46.5) 1.000 36 (37.3) 16 (37.2) 1.000 43 (57.3) 22 (55.0) 0.852
Age, yr 57.8±6.9 58.1±7.2 0.891 60.5±10.8 57.6±9.4 0.014 59.1±10.9 56.8±9.1 0.231 57.3±15.2 60.1±14.3 0.330
Caucasian race 34 (100) 15 (100) 1.000 89 (100) 43 (100) 1.000 96 (100) 43 (100) 1.000 82 (100) 40 (100) 1.000
HbA1c, % 7.9±1.6 7.0±1.9 0.093 7.5±1.2 7.0±1.9 0.070 8.6±1.7 9.1±2.1 0.140 8.2±1.7 7.84±2.2 0.321
BMI, kg/m2 29.8±2.7 28.8±3.1 0.258 30.7±3.1 31.7±3.7 0.110 31.1±3.2 29.9±4.1 0.061 32.5±3.8 31.06±4.9 0.080
Duration of diabetes, yr 5.92±1.3 6.63±1.9 0.140 7.16±2.3 8.01±2.9 0.070 8.25±2.9 7.73±3.1 0.340 6.82±1.8 7.31±2.21 0.201

Values are expressed as number (%) or mean±SD.

HbA1c, glycated hemoglobin; BMI, body mass index.

aGroup A (patients on metformin, glimepiride and insulin), B (patients on metformin and glimepiride), C (patients on metformin and insulin), and D (patients on insulin alone).

Table 3

Baseline Characteristics of the Participants in the Different Treatment Groupsa

Characteristic Group A Group B Group C Group D P value
Metformin 1 g bid+4 mg glimepiride+ glargine (10–38 units) Metformin 1 g bid+glimepiride 4 mg Metformin 1 g bid+glimepiride 2 mg Metformin 1 g bid+glargine (12–60 units) Metformin 1 g bid+premixed 70/30 (38–140 units) Glargine (10–65 units)+regular insulin (15–75 units) Premixed insulin 70/30 (35–150 units)
No. of patients in subgroup - 62 27 58 38 51 31
No. of total patients in group 34 89 96 82 -
Male sex 18 (52.9) 42 (47.2) 36 (37.3) 43 (52.4) 0.201
Age, yr 57.8±6.9 60.5±10.8 59.1±10.9 57.3±15.2 0.499
Arabic race 34 (100) 89 (100) 96 (100) 82 (100) -
HbA1c, % (mmol/mol) 7.9±1.6 (63±17.5) 7.5±1.2 (58±13.1) 8.6±1.7 (70±18.6) 8.2±1.7 (66±18.6) <0.001
BMI, kg/m2 29.8±2.7 30.7±3.1 31.1±3.2 32.5±3.8 <0.001
Duration of diabetes, yr 5.92±1.3 7.16±2.3 8.25±2.9 6.82±1.8 <0.001

Values are expressed as number (%) or mean±SD.

bid, twice a day; HbA1c, glycated hemoglobin; BMI, body mass index.

aGroup A (patients on metformin, glimepiride and insulin), B (patients on metformin and glimepiride), C (patients on metformin and insulin), and D (patients on insulin alone).

Table 4

Characteristics of the Patients Who Suffered a Hypoglycemic Event during Ramadan and the Preceding Month

Characteristic Group Aa Group Ba Group Ca Group Da
Preb Ramadan Preb Ramadan Preb Ramadan Preb Ramadan
No. of patients 2 - 3 - 9 1 7 -
Male sex 1 (50) - 1 (33) - 5 (56) 1 (100) 4 (57) -
Age, yr 51.5±1.5 - 67±5.3 - 64±8.4 66 56.7±15 -
BMI, kg/m2 31.2±1.0 - 29.1±1.7 - 30.2±1.1 29.6 31.3±1.2 -
Duration of diabetes, yr 6.1±1.1 - 6.9±0.7 - 8.3±0.9 8 6.9±1.2 -
HbA1c, % 8.1±0.9 - 7.6±0.8 - 8.5±0.6 8.7 7.9±0.5 -
Plasma glucose during event, mmol/L 55±2.0 - 54±6.3 - 49±3.2 53 54±4.1 -
Timing of event 10:00–11:30 AM - 1:00–2:30 PM - 12:30–5:00 PM 2:40 PM 2:00–6:30 PM -

Values are expressed as number (%) or mean±SD.

BMI, body mass index; HbA1c, glycated hemoglobin.

aGroup A (patients on metformin, glimepiride, and insulin), B (patients on metformin and glimepiride), C (patients on metformin and insulin), and D (patients on insulin alone); bDuring the month preceding Ramadan.

Similar articles